{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:40:08Z","timestamp":1748688008696,"version":"3.41.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Farma Italy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01407-0","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:34:05Z","timestamp":1746790445000},"page":"1771-1785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Anna","family":"Balato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Maifredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona Serao","family":"Creazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Antonacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Tonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diletta","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Vassellatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Cipelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Casoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"1407_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82:1045\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"1407_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2147\/CCID.S402453","volume":"16","author":"HM Alotaibi","year":"2023","unstructured":"Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545\u201352.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1407_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/fampra\/cmae037","volume":"41","author":"F Lapi","year":"2024","unstructured":"Lapi F, Marconi E, Casoli L, Tedeschi A, Giomi B, Cricelli C. Epidemiology and clinical correlates of hidradenitis suppurativa in primary care in Italy. Fam Pract. 2024;41:711\u20138.","journal-title":"Fam Pract"},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","volume":"157","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O\u2019Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021;157:924\u201331.","journal-title":"JAMA Dermatol"},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18.","journal-title":"Nat Rev Dis Primers"},{"key":"1407_CR6","first-page":"1","volume":"29","author":"A Miller","year":"2024","unstructured":"Miller A, Shahzeidi P, Bernhardt M. An update on current clinical management and emerging treatments in hidradenitis suppurativa. Skin Therapy Lett. 2024;29:1\u20136.","journal-title":"Skin Therapy Lett"},{"key":"1407_CR7","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.3390\/ijerph18136709","volume":"18","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, et\u00a0al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18:6709.","journal-title":"Int J Environ Res Public Health"},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, et\u00a0al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1407_CR9","first-page":"868","volume":"22","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Fritz K, et\u00a0al. S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa-Short version. J Dtsch Dermatol Ges. 2024;22:868\u201389.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1407_CR10","volume":"15","author":"ER Agnese","year":"2023","unstructured":"Agnese ER, Tariche N, Sharma A, Gulati R. The pathogenesis and treatment of hidradenitis suppurativa. Cureus. 2023;15: e49390.","journal-title":"Cureus"},{"issue":"Suppl 5","key":"1407_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1610-0387.2012.08006.x","volume":"10","author":"CC Zouboulis","year":"2012","unstructured":"Zouboulis CC, Bechara FG, Fritz K, et\u00a0al. S1-leitlinie zur therapie der hidradenitis suppurativa\/acne inversa* (ICD-10 ziffer: L73.2) [S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa * (number ICD-10 L73.2)]. J Dtsch Dermatol Ges. 2012;10(Suppl 5):S1\u201331. https:\/\/doi.org\/10.1111\/j.1610-0387.2012.08006.x.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1407_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/immuno4010004","volume":"4","author":"R Chen","year":"2024","unstructured":"Chen R, Guo R, Petty AJ, Jaleel T. Immune dysregulation and current targeted biologics in hidradenitis suppurativa. Immuno. 2024;4:57\u201376.","journal-title":"Immuno"},{"key":"1407_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.5114\/ada.2022.115323","volume":"39","author":"M Gierek","year":"2022","unstructured":"Gierek M, Ocha\u0142a-Gierek G, Kitala D, \u0141abu\u015b W, Bergler-Czop B. Surgical management of hidradenitis suppurativa. Postepy Dermatol Alergol. 2022;39:1015\u201320.","journal-title":"Postepy Dermatol Alergol"},{"key":"1407_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, et\u00a0al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80:60-69.e2.","journal-title":"J Am Acad Dermatol"},{"key":"1407_CR15","first-page":"1061","volume":"20","author":"A Tsentemeidou","year":"2022","unstructured":"Tsentemeidou A, Sotiriou E, Ioannides D, Vakirlis E. Hidradenitis suppurativa-related expenditure, a call for awareness: systematic review of literature. J Dtsch Dermatol Ges. 2022;20:1061\u201372.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1407_CR16","first-page":"729","volume-title":"Dermatologic surgery","author":"HJ Hurley","year":"1989","unstructured":"Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk HH, editor. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729\u201339."},{"key":"1407_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019","volume":"10","author":"M Napolitano","year":"2017","unstructured":"Napolitano M, Megna M, Timoshchuk EA, et\u00a0al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105\u201315.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1407_CR18","unstructured":"Monfrecola G, Megna M. Classification and severity scales. In: Micali G., Hidradenitis Suppurativa: A Diagnostic Atlas. 2017, Wiley-Blackwell ISBN: 978-1-119-42433-8"},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184\u201390.","journal-title":"Dermatology"},{"key":"1407_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000508787","volume":"236","author":"G Kokolakis","year":"2020","unstructured":"Kokolakis G, Wolk K, Schneider-Burrus S, et\u00a0al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236:421\u201330.","journal-title":"Dermatology"},{"key":"1407_CR21","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2147\/CCID.S301794","volume":"16","author":"CL Snyder","year":"2023","unstructured":"Snyder CL, Chen SX, Porter ML. Obstacles to early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol. 2023;16:1833\u201341.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1407_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","volume":"14","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Kirby J, Ingram JR, et\u00a0al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther (Heidelb). 2024;14:83\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1407_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.20344\/amp.18916","volume":"36","author":"J Cabete","year":"2023","unstructured":"Cabete J, Apar\u00edcio Martins I. Recomenda\u00e7\u00f5es na abordagem do doente com hidradenite supurativa [Guidelines for the management of patients with hidradenitis suppurativa]. Acta Med Port. 2023;36:133\u20139.","journal-title":"Acta Med Port"},{"key":"1407_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14737167.2021.1895753","volume":"22","author":"K G\u00e1sp\u00e1r","year":"2022","unstructured":"G\u00e1sp\u00e1r K, Hunor Gergely L, Jenei B, et\u00a0al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res. 2022;22:399\u2013408.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1407_CR25","volume":"4","author":"C Howard-James","year":"2023","unstructured":"Howard-James C, Tobin AM. An analysis of direct and indirect costs in hidradenitis suppurativa. Skin Health Dis. 2023;4: e306.","journal-title":"Skin Health Dis"},{"key":"1407_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255560","volume":"16","author":"VG Frings","year":"2021","unstructured":"Frings VG, Sch\u00f6ffski O, Goebeler M, Presser D. Economic analysis of the costs associated with hidradenitis suppurativa at a German University Hospital. PLoS ONE. 2021;16: e0255560.","journal-title":"PLoS ONE"},{"key":"1407_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/bjd.14976","volume":"176","author":"N Desai","year":"2017","unstructured":"Desai N, Shah P. High burden of hospital resource utilization in patients with hidradenitis suppurativa in England: a retrospective cohort study using hospital episode statistics. Br J Dermatol. 2017;176:1048\u201355.","journal-title":"Br J Dermatol"},{"key":"1407_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/jdv.14770","volume":"32","author":"IE Deckers","year":"2018","unstructured":"Deckers IE, Dahi Y, van der Zee HH, Prens EP. Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures. J Eur Acad Dermatol Venereol. 2018;32:459\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1407_CR29","doi-asserted-by":"publisher","first-page":"E94","DOI":"10.1503\/cjs.003119","volume":"63","author":"E Shavit","year":"2020","unstructured":"Shavit E, Pawliwec A, Alavi A, George R. The surgeon\u2019s perspective: a retrospective study of wide local excisions taken to healthy subcutaneous fat in the management of advanced hidradenitis suppurativa. Can J Surg. 2020;63:E94\u20139.","journal-title":"Can J Surg"},{"key":"1407_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A, et\u00a0al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81:76\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"1407_CR31","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.1016\/j.jval.2023.03.2066","volume":"26","author":"J Voorham","year":"2023","unstructured":"Voorham J, Tran T, Ploug U, Keal A, Beaty S, Shang A. RWD36 Healthcare resource utilization in patients with hidradenitis suppurativa in five European countries and the USA using real world evidence. Value Health. 2023;26:S367.","journal-title":"Value Health"},{"key":"1407_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s13555-023-00954-8","volume":"13","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Rahawi K, Duan Y, Lane M, Amin AZ, Sayed CJ. Effect of biologics on the need for procedural interventions, systemic medications, and healthcare utilization in patients with hidradenitis suppurativa: real-world data from the UNITE registry. Dermatol Ther (Heidelb). 2023;13:1577\u201385.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01407-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T10:00:04Z","timestamp":1748685604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01407-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01407-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arianna Tonelli, Diletta Valsecchi, Donatella Vassellatti, Lucia Casoli are employees of Novartis Farma Italy. Marina Venturini has served as an advisory board member and\/or consultant and has received fees\/speaker\u2019s honoraria and\/or has participated in clinical trials for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. Riccardo Cipelli is an employee of IQVIA Solutions Italy. Anna Balato, Massimiliano Scalvenzi, Caterina Foti, Giovanni Maifredi, Simona Serao Creazzola, Stefania Antonacci, and Alessandra Ori have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was approved by the Ethics Committees of all participating Clinical Centers and LHUs, including the Independent Ethics Committee (IEC) of Bari (approval no. 7265, dated 25 January 2023), the Ethics Committee of the University of Campania \u201cLuigi Vanvitelli\u201d\u2014AORN \u201cOspedale dei Colli\u201d (approval no. 5870\/2022, dated 31 March 2022), the Campania Centro Ethics Committee (protocol CE no. 390, dated 28 July 2022), the Ethics Committee of the University of Naples Federico II\u2014AORN A. Cardarelli (approval no. 07\/22, dated 21 July 2022), and the Ethics Committee of Brescia (approval no. NP5634, dated 26 January 2023). All subjects provided written informed consent prior to enrollment and consented to the use of their data for publication. All procedures performed were in accordance with the 1964 Helsinki Declaration and its later amendments, Good Clinical Practice, and local applicable regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}